【瑞康医药：拟收购浙江衡玖76.01%股权】瑞康医药公告，公司下属子公司吉祥山（山东）医学科技有限公司拟以现金方式收购关联方烟台衡悦健康科技合伙企业（有限合伙）持有的浙江衡玖医疗器械有限责任公司76.01%股权，交易金额为1.51亿元。浙江衡玖整体估值为1.99亿元，交易完成后，浙江衡玖将成为瑞康医药的合并报表子公司。此次交易构成关联交易，但不构成重大资产重组。

金融界2025-02-21

瑞康医药公告，公司下属子公司吉祥山（山东）医学科技有限公司拟以现金方式收购关联方烟台衡悦健康科技合伙企业（有限合伙）持有的浙江衡玖医疗器械有限责任公司76.01%股权，交易金额为1.51亿元。浙江衡玖整体估值为1.99亿元，交易完成后，浙江衡玖将成为瑞康医药的合并报表子公司。此次交易构成关联交易，但不构成重大资产重组。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2513260433?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-02-21 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2513260433","market":"us","top_or_hot":-1,"title":"【瑞康医药：拟收购浙江衡玖76.01%股权】瑞康医药公告，公司下属子公司吉祥山（山东）医学科技有限公司拟以现金方式收购关联方烟台衡悦健康科技合伙企业（有限合伙）持有的浙江衡玖医疗器械有限责任公司76.01%股权，交易金额为1.51亿元。浙江衡玖整体估值为1.99亿元，交易完成后，浙江衡玖将成为瑞康医药的合并报表子公司。此次交易构成关联交易，但不构成重大资产重组。","media":"金融界","content":"<div>\n<p>瑞康医药公告，公司下属子公司吉祥山（山东）医学科技有限公司拟以现金方式收购关联方烟台衡悦健康科技合伙企业（有限合伙）持有的浙江衡玖医疗器械有限责任公司76.01%股权，交易金额为1.51亿元。浙江衡玖整体估值为1.99亿元，交易完成后，浙江衡玖将成为瑞康医药的合并报表子公司。此次交易构成关联交易，但不构成重大资产重组。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/02/21212048319655.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【瑞康医药：拟收购浙江衡玖76.01%股权】瑞康医药公告，公司下属子公司吉祥山（山东）医学科技有限公司拟以现金方式收购关联方烟台衡悦健康科技合伙企业（有限合伙）持有的浙江衡玖医疗器械有限责任公司76.01%股权，交易金额为1.51亿元。浙江衡玖整体估值为1.99亿元，交易完成后，浙江衡玖将成为瑞康医药的合并报表子公司。此次交易构成关联交易，但不构成重大资产重组。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【瑞康医药：拟收购浙江衡玖76.01%股权】瑞康医药公告，公司下属子公司吉祥山（山东）医学科技有限公司拟以现金方式收购关联方烟台衡悦健康科技合伙企业（有限合伙）持有的浙江衡玖医疗器械有限责任公司76.01%股权，交易金额为1.51亿元。浙江衡玖整体估值为1.99亿元，交易完成后，浙江衡玖将成为瑞康医药的合并报表子公司。此次交易构成关联交易，但不构成重大资产重组。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-02-21 21:20 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/02/21212048319655.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>瑞康医药公告，公司下属子公司吉祥山（山东）医学科技有限公司拟以现金方式收购关联方烟台衡悦健康科技合伙企业（有限合伙）持有的浙江衡玖医疗器械有限责任公司76.01%股权，交易金额为1.51亿元。浙江衡玖整体估值为1.99亿元，交易完成后，浙江衡玖将成为瑞康医药的合并报表子公司。此次交易构成关联交易，但不构成重大资产重组。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/02/21212048319655.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0185","symbol_name":"二线龙头","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/02/21212048319655.shtml","article_id":"2513260433","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2513260433","pubTimestamp":1740144007,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"瑞康医药公告，公司下属子公司吉祥山（山东）医学科技有限公司拟以现金方式收购关联方烟台衡悦健康科技合伙企业（有限合伙）持有的浙江衡玖医疗器械有限责任公司76.01%股权，交易金额为1.51亿元。浙江衡玖整体估值为1.99亿元，交易完成后，浙江衡玖将成为瑞康医药的合并报表子公司。此次交易构成关联交易，但不构成重大资产重组。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159883":"医疗器械","BK0185":"二线龙头","BK1583":"高瓴概念","BK0197":"中小创蓝筹","09997":"康基医疗","BK1100":"医疗保健设备","BK0132":"高送转概念","BK0070":"员工持股","BK1574":"生物医药B类股","BK1222":"医疗保健用品","BK0077":"质押式回购","002589":"瑞康医药","09996":"沛嘉医疗-B","BK0250":"批发"},"translate_title":"[Ruikang Pharmaceutical: intends to acquire 76.01% equity of Zhejiang Hengjiu] Ruikang Pharmaceutical announced that Jixiangshan (Shandong) Medical Technology Co., Ltd., a subsidiary of the company, intends to acquire 76.01% equity of Zhejiang Hengjiu Medical Devices Co., Ltd. held by Yantai Hengyue Health Technology Partnership (Limited Partnership), a related party, in cash, with a transaction amount of 151 million yuan. The overall valuation of Zhejiang Hengjiu is 199 million yuan. After the transaction is completed, Zhejiang Hengjiu will become a consolidated subsidiary of Ruikang Pharmace","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159883":1,"002589":1,"09997":1,"09996":1},"content_text":"瑞康医药公告，公司下属子公司吉祥山（山东）医学科技有限公司拟以现金方式收购关联方烟台衡悦健康科技合伙企业（有限合伙）持有的浙江衡玖医疗器械有限责任公司76.01%股权，交易金额为1.51亿元。浙江衡玖整体估值为1.99亿元，交易完成后，浙江衡玖将成为瑞康医药的合并报表子公司。此次交易构成关联交易，但不构成重大资产重组。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2513260433","isCrawlerRequest":true}